Just summarising the data from this, it backed up many of the studies that have already been done, showing that users of various systems typically saw a reduction in Hba1C, and overall this was an average reduction of 1.1% in the mean Hba1C level. Participants time in range went from a majority not knowing to a majority exceeding 50%. Those who didn't use their systems full time saw less of an Hba1C reduction than those who did (t-tested using the Abbott data, where it's obvious whether someone is using a system full time based on finite lifespan of the sensor and expenditure on consumables).
What was interesting for me was that fewer Abbott Freestyle Libre users reported a reduction in frequency and severity hypoglycaemic events than CGM users, which is unsurprising given the lack of alarming. For most systems, frequency reduction exceeded more than 60%, whereas for Libre it was 53%, and in terms of severity reduction, for other systems more than 60% reported a benefit but only 39% of Libre responders did so.
Comparing NHS users with paying users showed there was correlation between whether someone was funded and reduction in Hba1C, however, it's worth bearing in mind that most NHS funded users receive CGM as a result of impaired hypo awareness, so they may not be attempting to improve their management in such a way that presents with a lower Hba1C. Having said that, other research has shown that lower Hba1Cs tend to be correlated with fewer severe hypos, so they may still have benefited.
What was notable was that those who responded to the survey generally had a better distribution of Hba1C than the UK NDA showed for type 1s pre use of a system, and a much better distribution post use of one.
Anyway, read the report for further details. There's plenty in there!
